LATAM intelligence
Built for Latin America, not translated into it.
COFEPRIS, INVIMA, ISP, ANMAT, ANVISA, ANS, ADRES. Latin American pharmacy is the whole business, not a go-to-market segment. Production-proven in Bolivia today.
Latin American generic substitution economics are not US generic substitution economics. Latin American counterfeit networks are not European counterfeit networks. Latin American prescriber fraud patterns are not Medicaid prescriber fraud patterns. A detection rule written for US payers does not understand any of them. Inspector AI was built from day one for Latin American pharmacy claims, regulators, and networks. Current production deployment is in Bolivia. Latin America is the whole business — and as we enter new markets across the region, we build detection logic for each one to match its local pharmacy economy and regulatory framework.
Why regional specificity is a moat
A detection rule is only as useful as its assumptions about the market it runs in. Assumptions that hold in Minnesota do not hold in Monterrey. Pharmacy networks, branded-generic relationships, reimbursement flows, counterfeit supply chains, prescriber fraud patterns — every one of these varies by country, and a rule trained on the wrong one will over-flag legitimate claims and under-flag the real schemes. Regional specificity is not a feature. It is the difference between a platform that works and one that does not.
Latin America is the whole focus
Inspector AI does not sell into US, European, or Asian markets. The entire roadmap is regional. Current production deployment is in Bolivia, where the platform runs live on real pharmacy claims. Every new market we enter across Latin America gets its own detection logic — built from scratch, tuned to the local pharmacy economy, the local regulatory framework, and the local prescribing culture. Latin America is not a vertical for us. It is the product.
Regulators we understand
COFEPRIS (Mexico) regulates medications, device safety, and pharmacy licensing. INVIMA (Colombia) is the equivalent national health authority. ISP (Chile) oversees pharmaceutical products. ANMAT (Argentina) handles drug regulation and market surveillance. ANVISA (Brazil) regulates pharmaceuticals and works alongside ANS on health plan oversight. ADRES (Colombia) is the claims-payment entity for the public insurance system. Inspector AI's detection logic is written knowing each of these regulators exists and what they require. We do not claim certification by any of them — we do claim awareness, and that is more than most platforms offer.
Schemes global tools would miss
Generic substitution arbitrage: on the 50,000-subscriber Latin American book where Inspector AI measured WAFL, 71% of branded products had a generic available, under 5% were dispensed as generic, and 99.8% of the potential substitutions would have been clinically safe. The observed gap on that book alone was $4.53 million of detectable loss in one year — a category that tools trained on US data would not have measured because they do not understand the local economics. Brazilian counterfeit pharmacy networks in high-value GLP-1 medications, currently under active Anvisa enforcement. Argentine prescriber fraud rings with fake prescriptions issued against public health systems. Each of these is invisible to a detection tool trained on Medicaid data. For the full category breakdown, see WAFL.
of Inspector AI's business is Latin American pharmacy. Not a vertical. The product.
Talk to someone who speaks your market
A three-week proof of concept on your real pharmacy data, run by people who know the difference between COFEPRIS and the FDA.